according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin / Pyrantel Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road

Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Short-term (acute) aquatic

hazard

Category 1

Long-term (chronic) aquatic

hazard

Category 1

GHS label elements

Hazard pictograms

¥2>

Signal word : Warning

Hazard statements : H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P273 Avoid release to the environment.

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Revision Date: Date of last issue: 04.04.2023 Version SDS Number: 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Response:

P391 Collect spillage.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 8.6 %

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6	>= 5 - < 10
Sodium chloride	7647-14-5	>= 1 - < 5
Ivermectin	70288-86-7	>= 0.0025 - < 0.025

4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact If in eves, rinse well with water,

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

the skin. Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of

delayed

Protection of first-aiders No special precautions are necessary for first aid responders.

Notes to physician Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 52863-00029
 Date of first issue: 02.02.2015

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulphur oxides Metal oxides

Chlorine compounds

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: : tive equipment and emer-

gency procedures

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 52863-00029 Date of first issue: 02.02.2015 3.1

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation

Advice on safe handling Do not breathe dust.

> Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Keep in properly labelled containers. Conditions for safe storage

Store in accordance with the particular national regulations.

Do not store with the following product types: Materials to avoid

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6	TWA	250 μg/m3 (OEB 2)	Internal
Ivermectin	70288-86-7	TWA	30 μg/m3 (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 μg/100 cm2	Internal

Engineering measures All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face contain-

ment devices).

Minimize open handling.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type

Material Chemical-resistant gloves

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : brown

Odour : No data available

Odour Threshold : No data available

pH : 4 - 6 (20 °C)

(as aqueous solution)

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Hazardous decomposition

products

Oxidizing agents

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation Skin contact

Ingestion Eye contact

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Revision Date: Date of last issue: 04.04.2023 Version SDS Number: 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Acute toxicity

Not classified based on available information.

Product:

Acute toxicity estimate: > 5,000 mg/kg Acute oral toxicity

Method: Calculation method

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Acute oral toxicity : LD50 (Rat): > 24,000 mg/kg

LD50 (Mouse): > 24,000 mg/kg

LD50 (Dog): 2,000 mg/kg

Sodium chloride:

Acute oral toxicity LD50 (Rat): 3,550 mg/kg

: LC50 (Rat): > 42 mg/l Acute inhalation toxicity

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity LD50 (Rabbit): > 5,000 mg/kg

Ivermectin:

Acute oral toxicity LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil Remarks: No mortality observed at this dose.

Acute inhalation toxicity LC50 (Rat): 5.11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

LD50 (Rabbit): 406 mg/kg Acute dermal toxicity

LD50 (Rat): > 660 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Sodium chloride:

Rabbit **Species**

Result No skin irritation

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Revision Date: Version SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Ivermectin:

Species Rabbit

No skin irritation Result

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Sodium chloride:

Species Rabbit

Result No eye irritation

Ivermectin:

Species Rabbit

Result Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Sodium chloride:

Test Type Local lymph node assay (LLNA)

Exposure routes Skin contact **Species** Mouse Result negative

Ivermectin:

Dermal Exposure routes **Species** Humans

Result Does not cause skin sensitisation.

Germ cell mutagenicity

Not classified based on available information.

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-

methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Sodium chloride:

Genotoxicity in vitro Test Type: In vitro mammalian cell gene mutation test

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Saccharomyces cerevisiae, gene mutation assay

(in vitro) Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: positive

Test Type: Chromosome aberration test in vitro

Result: positive

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Intraperitoneal injection

Result: positive

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts

Result: negative

Test Type: Mouse Lymphoma

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Sodium chloride:

Species : Rat Application Route : Ingestion

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Exposure time : 2 Years
Result : negative

Ivermectin:

Species : Rat Application Route : Oral

NOAEL : 1.5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2.0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Reproductive toxicity

Not classified based on available information.

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Effects on foetal develop-

Test Type: Embryo-foetal development Species: Rat

ment

Application Route: Oral

Developmental Toxicity: NOAEL: 3,000 mg/kg body weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0.4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

STOT - single exposure

Not classified based on available information.

Components:

Ivermectin:

Target Organs : Central nervous system Assessment : Causes damage to organs.

STOT - repeated exposure

Not classified based on available information.

Components:

Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 30 mg/kg
Application Route : Ingestion
Exposure time : 3 d

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 600 mg/kg Application Route : Oral

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Exposure time : 19 d

Remarks : No significant adverse effects were reported

Species : Dog

NOAEL : 600 mg/kg Application Route : Oral

Application Route : Oral Exposure time : 30 d

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 600 mg/kg Application Route : Oral Exposure time : 90 d

Remarks : No significant adverse effects were reported

Sodium chloride:

Species : Rat

LOAEL : 2,533 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Ivermectin:

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 0.4 mg/kg
LOAEL : 0.8 mg/kg
Application Route : Oral
Exposure time : 3 Months

Target Organs : spleen, Bone marrow, Kidney

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea,

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

Headache, Dizziness, Fever

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Sodium chloride:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 4,136 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50: > 2,000 mg/l Exposure time: 96 h

Toxicity to microorganisms : EC10: > 1,000 mg/l

Toxicity to fish (Chronic tox-

icity)

NOEC: 252 mg/l

Exposure time: 33 d

Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 314 mg/l Exposure time: 21 d

Species: Daphnia pulex (Water flea)

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

plants mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

10,000

M-Factor (Chronic aquatic

toxicity)

10,000

Persistence and degradability

Components:

Ivermectin:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 240 d

Bioaccumulative potential

Components:

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-

octanol/water

log Pow: 3.22

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 52863-00029
 Date of first issue: 02.02.2015

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Ivermectin)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Ivermectin)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 956

aircraft)

Packing instruction (passen- : 956

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ivermectin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

16. OTHER INFORMATION

Revision Date : 30.09.2023

Further information

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

according to the Globally Harmonized System



Ivermectin / Pyrantel Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 52863-00029 Date of first issue: 02.02.2015

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN